Seven Biotech Companies to Know in the Netherlands

Why It Matters

Dutch biotech’s ability to attract deep capital and generate lucrative exits signals a mature innovation pipeline that can fuel global drug development, while also exposing a gap in late‑stage commercialization capacity within the Netherlands.

Key Takeaways

• Netherlands biotech hubs attract €300M+ recent funding
• Leyden Labs raised $140M Series B for nasal antibodies
• Merus acquired for $8B, boosting oncology pipeline
• NorthSea advances SEFA platform targeting NASH
• uniQure shows promising Huntington’s disease gene therapy data

Pulse Analysis

The Netherlands has cultivated a uniquely dense life‑science landscape, leveraging concentrated clusters like Leiden Bio Science Park and generous government incentives such as the WBSO tax credit. This ecosystem nurtures a high concentration of talent, research institutions, and venture capital, allowing firms to scale quickly and attract multinational interest. As a result, Dutch biotech companies routinely secure sizable financing rounds, with recent Series A, B, and C deals collectively exceeding €300 million, positioning the country as a launchpad for innovative therapeutic platforms.

Among the most compelling Dutch innovators are Leyden Labs, which is pioneering intranasal antibody sprays to block respiratory viruses at the point of entry, and Merus, whose bispecific and trispecific antibody platforms have secured late‑stage trials and culminated in an $8 billion acquisition by Genmab. Parallel advances include NorthSea Therapeutics’ engineered fatty‑acid (SEFA) candidates for metabolic disease, ProQR’s ADAR‑mediated RNA editing platform, Scenic Biotech’s genetic‑modifier discovery approach, and uniQure’s AAV‑based gene therapies that have already delivered an FDA‑approved hemophilia B treatment and promising Huntington’s disease data. VectorY adds a novel twist by delivering antibodies via AAV vectors, aiming to overcome dosing challenges in neuro‑muscular disorders.

These successes, however, reveal a broader industry pattern: Dutch firms excel at early‑stage innovation but often exit through acquisition to access the deep capital and global commercialization networks of larger biopharma groups. While this validates the quality of Dutch platform biology, it also underscores a need for domestic infrastructure that can shepherd late‑stage development and market launch. Investors and policymakers are therefore watching the balance between nurturing new start‑ups and building the scale required to retain high‑value assets within the Netherlands, a dynamic that will shape the country’s biotech trajectory in the coming years.